المؤلفون: City of Hope Medical Center, Miyarisan Pharmaceuticals, Co., Ltd., National Cancer Institute (NCI)

المصدر: Dman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, CuY, Ma V, Llamas M, Hsu J, Zeng Z, Salg N, Salg S, Malhotra J, Chawla N, ChehrazRaffle A, MuddasanR, Glece J, Reg L, Trent J, TakahashM, Oka K, HashS, KortylewskM, Hhlander SK, Pal SK. Nolumab plus umab wh or whout le bacterl supplementatn metastat renal cell carcoma: a randomed phase 1 trl. Nat Med. 2022 Apr;28(4):704-712. do 10.1038/s41591-022-01694-6. Epub 2022 Feb 28.
Toma Y, eda T, Sakata S, SaruwatarK, Sato R, ama S, JodaT, Akae K, huka S, SaekS, SakagamT. Assoctn of Probt Clostrm butyrum Therapy wh Surval and Response to mune Checkpot Blockade Patnts wh Lung Cancer. Cancer munol Res. 2020 Oct;8(10):1236-1242. do 10.1158/2326-6066.C-20-0051. Epub 2020 Jul 14.
Toma Y, Goto Y, Sakata S, amura K, Memura A, Oka K, HayashA, JodaT, Akae K, AnaM, Hamada S, ama S, SaruwatarK, SaekS, TakahashM, eda T, SakagamT. Clostrm butyrum therapy restores the decreased effacy of mune checkpot blockade lung cancer patnts receg proton pump hors. Oncomunology. 2022 May 27;11(1):2081010. do 10.1080/2162402X.2022.2081010. eCollectn 2022.
Toma Y, Sakata S, amura K, ama S, JodaT, SaruwatarK, Hamada S, Akae K, AnaM, Fukusa K, TakakA, Tsukamoto H, Goto Y, Motozono C, Sugata K, Satou Y, Ueno T, eda T, SakagamT. Assoctn of Clostrm butyrum Therapy Usg the Le Bacterl Product CBM588 wh the Surval of Patnts wh Lung Cancer Receg Chemomunotherapy Combatns. Cancers (Basel). 2023 Dec 21;16(1):47. do 10.3390/cancers16010047.
Paz Del Socorro T, Oka K, Boulard O, TakahashM, Poul LF, HayashA, Chamalard M. The btherapeut Clostrm butyrum MA588 stra potenttes enterotropm of Rorgammat+Treg and PD-1 blockade effacy. Gut Mrobes. 2024 Jan-Dec;16(1):2315631. do 10.1080/19490976.2024.2315631. Epub 2024 Feb 22.
An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell Carcinoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06399419Test

المصدر: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 Expression

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06364410Test

المصدر: A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic Cancers

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06362369Test

المصدر: Observational Basket Study to Predict Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06349642Test

Other URLs: https://www.mayo.edu/research/clinical-trialsTest

المصدر: Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06265285Test

Other URLs: https://www.mayo.edu/research/clinical-trialsTest

المصدر: A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06264921Test

المصدر: Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06246968Test

Other URLs: http://www.mskcc.orgTest

المصدر: A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06242470Test

المؤلفون: Arcus Biosciences, Inc.

المصدر: A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06191796Test

المؤلفون: Breast Cancer Research Foundation

المصدر: A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06179303Test